253 related articles for article (PubMed ID: 34144267)
21. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Hong S; Jiang W; Xu C
J Hematol Oncol; 2014 May; 7():39. PubMed ID: 24886678
[TBL] [Abstract][Full Text] [Related]
24. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
25. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
26. The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.
Vallejo-Díaz J; Chagoyen M; Olazabal-Morán M; González-García A; Carrera AC
Trends Cancer; 2019 Apr; 5(4):233-244. PubMed ID: 30961830
[TBL] [Abstract][Full Text] [Related]
27. Targeting EGFR and PI3K pathways in ovarian cancer.
Glaysher S; Bolton LM; Johnson P; Atkey N; Dyson M; Torrance C; Cree IA
Br J Cancer; 2013 Oct; 109(7):1786-94. PubMed ID: 24022196
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
30. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
31. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
32. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.
Mallmann-Gottschalk N; Sax Y; Kimmig R; Lang S; Brandau S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546690
[TBL] [Abstract][Full Text] [Related]
33. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
34. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
35. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
[TBL] [Abstract][Full Text] [Related]
36. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Jabbarzadeh Kaboli P; Leong MP; Ismail P; Ling KH
Pharmacol Rep; 2019 Feb; 71(1):13-23. PubMed ID: 30343043
[TBL] [Abstract][Full Text] [Related]
38. Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells.
Cheng JC; Klausen C; Leung PC
Mol Endocrinol; 2010 Aug; 24(8):1569-80. PubMed ID: 20610539
[TBL] [Abstract][Full Text] [Related]
39. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
[TBL] [Abstract][Full Text] [Related]
40. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
